CHICAGO — Improvements in response duration and side effect profile seen in the KEYNOTE-045 trial of pembrolizumab establish this therapy “as a standard of care” for patients with previously treated, metastatic urothelial cancer, according to Matthew Galsky, MD, professor of medicine (hematology and medical oncology) and urology at the Icahn School of Medicine at Mount Sinai Hospital in New York.